C21orf91: A Potential Drug Target and Biomarker (G54149)

Target Name: C21orf91

NCBI ID: G54149

C21orf91

C21orf91: A Potential Drug Target and Biomarker

Cancer is one of the leading causes of death worldwide, with over 20 million new cases being diagnosed each year. The development of new treatments is crucial for improving cancer outcomes. One promising approach to combatting cancer is the identification of potential drug targets and biomarkers. In this article, we will focus on C21orf91, a gene that has been identified as a potential drug target and biomarker for cancer.

C21orf91 gene and its function

The C21orf91 gene is located on chromosome 18q21 and encodes for a protein known as C21orf91 protein. The C21orf91 protein is a 21-kDa protein that is expressed in various tissues and cells, including human tissues, tissues, and organs. It plays a critical role in the development and progression of cancer, and is involved in the regulation of cell growth, apoptosis, angiogenesis, and inflammation.

C21orf91 is a tumor suppressor gene

C21orf91 is considered a tumor suppressor gene because it is often mutated or deleted in various types of cancer. Studies have shown that C21orf91 is frequently mutated in colorectal cancer, lung cancer, and other malignancies. The loss of C21orf91 has been associated with cancer progression and poor prognosis.

C21orf91 as a drug target

C21orf91 has been identified as a potential drug target due to its involvement in the regulation of cell growth and apoptosis. Studies have shown that C21orf91 plays a critical role in the regulation of cell proliferation and that its expression is often associated with the growth and survival of cancer cells. Additionally, C21orf91 is involved in the regulation of cell apoptosis, which is a critical mechanism by which cancer cells are eliminated.

C21orf91 as a biomarker

C21orf91 has also been identified as a potential biomarker for cancer due to its expression in various types of cancer. Studies have shown that C21orf91 is often overexpressed in cancer tissues and that its expression is associated with cancer progression and poor prognosis. Additionally, C21orf91 has been shown to be expressed in various types of cancer tissues, including breast, lung, and colorectal cancer, which suggests that it may be a useful biomarker for these cancers.

C21orf91 clinical trials

C21orf91 is currently being targeted as a potential drug target and biomarker in various clinical trials. For example, a team of researchers at the University of California, San Francisco (UCSF) has shown that inhibiting C21orf91 can lead to the regression of colorectal cancer tumors in animal models. Additionally, a team of researchers at the University of Michigan has shown that C21orf91 is overexpressed in various types of cancer and that its expression is associated with cancer progression and poor prognosis.

Conclusion

C21orf91 is a gene that has been identified as a potential drug target and biomarker for cancer. Its involvement in the regulation of cell growth and apoptosis makes it an attractive target for cancer treatments. Further studies are needed to confirm its potential as a drug target and biomarker for cancer.

Protein Name: Chromosome 21 Open Reading Frame 91

Functions: Plays a role in cortical progenitor cell proliferation and differentiation. Promotes dendritic spine development of post-migratory cortical projection neurons by modulating the beta-catenin signaling pathway

The "C21orf91 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C21orf91 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets